Continuing where they left off at the end of the second quarter, global biotechs recorded yet another positive quarter. However, the fundraising pace did slow down reflecting what proved to be a comparatively quiet summer period. Nevertheless, more than $4 billion was banked by public and private companies in the third quarter of 2013, a 29 percent drop from the almost $6 billion that was raised in the second quarter and 17 percent shy of the total generated in Q1 2013. Read More
Not only has the window for biotech initial public offerings (IPOs) remained wide open so far this year, but also the after-market performance of the newly minted public companies has been nothing short of amazing – recording a collective 68 percent increase in share price after hitting the markets. Not surprising then that companies on the biotech IPO runway have been anxious to take flight. Read More
